Navigation Links
Latest Drug for AMD, Beyond The Reach Of Common Man

Lucentis is the new drug which is claimed to be very effective in treating age-related macular degeneration (AMD) It is not been approved by the FDA //but is thought to replace another proven and cost effective drug. Lucentis is manufactured by Genentech and is already called the wonder drug. AMD is a chronic eye disease affecting 1.7 million Americans and a leading cause of blindness in the country.

Dr. Philip Rosenfeld, a macular-degeneration specialist in Miami said that the drug can be replaced by Avastin which has a very similar molecular structure. About 10,000 people were administered Avastin which has given very good results. Lucentis can't repair the irreversible retina damage but prevents the blood-vessel leakage in the back of the eye that causes damage. The patients suffer from distorted, wavy vision, and eventually a gap in the center of their vision. In the trails session itself Lucentis was found to have improved the patient’s eyesight by at least three lines on a vision chart.

The only disadvantage is that Lucentis will cost more than 100 times as much as the temporary fix. A dose of Avastin for the eye costs about $13 whereas Lucentis cost up to $3000 for a single dose. Doctors too will most likely turn to the more expensive drug. The problem is that Avastin has not been subjected to rigorous testing for AMD, and it would take Genentech years and huge amount of money to do those tests with Avastin. Megan Pace, spokeswoman for the company said that the cost factor would be taken care of by the company and hence patients need not worry about it.


'"/>




Page: 1

Related medicine news :

1. Latest device for identifying Melanomas
2. Latest discovery on Autism
3. Latest device for cardiac revival under test
4. Latest technique for asthma treatment
5. Latest drug shows promise in multiple myeloma
6. Latest Findings On The Deadly Disease - SARS
7. Latest Tumor Classification More Informative
8. The Latest Preventative Treatment Option for Prostate Cancer
9. Latest Research Shows That Multivitamins Might Not Prevent Infections In All Elderly
10. A Latest Study Links Fish To Stroke
11. Enhanced Gene Therapy Outcomes Following Latest Revolution And Refinement
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/31/2016)... ... 31, 2016 , ... More than 80 representatives of the Hepatitis B ... Cancer Foundation held an event on National Hepatitis Testing Day outside of Philadelphia City ... the leading cause of liver cancer. , Foundation leaders and the citywide coalition they ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... mix of advanced Artificial Intelligence (AI) and the latest in Clinical Patient ... center is integrating predictive analytic outputs directly into the clinical workflow. These insights ...
(Date:5/31/2016)... ... May 31, 2016 , ... Effective leaders not only drive service to the ... whole. On June 2, Northbound CEO Mike Neatherton and COO Paul Alexander will be ... opening plenary on “Leadership: The Journey to Authenticity” with Onsite Workshops CEO Miles Adcock ...
(Date:5/31/2016)... ... 31, 2016 , ... In his latest video, renowned AstroNumerologist ... humans. Using presidential candidate Donald Trump as an example, Kalsi describes the way ... not about adding numbers up,” says Kalsi. “It is about looking at each ...
(Date:5/31/2016)... ... 31, 2016 , ... TeaZa® Energy, LLC announces the launch of ... No Tobacco Day . The new flavor—Tropical TeaZa? Energy—will be available to customers ... , The new flavor is best described as a juicy, taste bud takeover. ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/26/2016)... , May 26, 2016 ... With Both Cost Savings and Overall Decreased ... (LSE: BTG), an international specialist healthcare company, has ... the 21st Annual Meeting of ISPOR (International Society ... of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres ...
(Date:5/26/2016)... Since its commercial introduction in ... life science tool for conducting genetic studies in a ... in its new report that the industry sits on ... by a range of new applications in the clinical ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the Human ...
Breaking Medicine Technology: